South Pharmaceutical is a leading producer of paclitaxel and its intermediates in the Chinese pharmaceutical industry. It is the developer of the national standard "Technical Regulations for the Cultivation of Taxus mairei and Paclitaxel Raw Material Forests in the South," and one of the largest planting bases for Taxus mairei and production bases for paclitaxel and its intermediates in China. The company emphasizes technological innovation and the construction of its research and development team, holding 8 PCT international invention patents and 23 Chinese invention patents.
South Pharmaceutical has a strong sense of social responsibility, focusing on environmental protection and green development. It has a comprehensive environmental management and occupational health and safety management system (EHS system).
福建(jian)南(nan)方(fang)制(zhi)藥(yao)股份有(you)(you)限(xian)公(gong)司(si)(證券代(dai)碼(ma):831207)成(cheng)立于(yu)2001年(nian)9月,致(zhi)力(li)于(yu)以紫杉(shan)醇原料藥(yao)為(wei)代(dai)表(biao)的抗(kang)腫瘤(liu)藥(yao)物(wu)的研發和生(sheng)產(chan),是一(yi)家集(ji)藥(yao)物(wu)種植、研發、生(sheng)產(chan)、銷售于(yu)一(yi)體(ti)的GMP制(zhi)藥(yao)企業。公(gong)司(si)旗(qi)下雪峰、瀚仙(xian)兩(liang)個廠區占地面積共13.1萬平方(fang)米,擁有(you)(you)4000畝優選南(nan)方(fang)紅豆(dou)杉(shan)種植基地。
南方制藥是中國(guo)制藥行業領先的(de)(de)紫(zi)杉烷類原料藥及中間體產(chan)品(pin)生(sheng)產(chan)企業,是國(guo)家(jia)標準《南方紅豆(dou)杉紫(zi)杉醇(chun)原料林豐產(chan)栽培技術規程》的(de)(de)制定者,是中國(guo)最大(da)的(de)(de)紅豆(dou)杉種(zhong)植基地和紫(zi)杉烷類產(chan)品(pin)生(sheng)產(chan)供應(ying)基地之一。公司(si)重視技術革新(xin)和研發(fa)隊伍的(de)(de)建設,現有(you)8項PCT國(guo)際(ji)發(fa)明(ming)專利、23項中國(guo)發(fa)明(ming)專利。
南方(fang)制藥富有(you)良好的(de)社會責任感(gan),致力于環境(jing)保(bao)護和綠色發展,擁(yong)有(you)完備(bei)的(de)環境(jing)管理(li)和職業(ye)健康安全管理(li)體系(xi)(EHS體系(xi))。
Fujian South Pharmaceutical Co., Ltd. (Stock Code: 831207) was established in September 2001. It is committed to the research and production of anti-tumor drugs, with paclitaxel as its representative, and is a GMP pharmaceutical enterprise integrating drug planting, research, production, and sales. The company's two factory areas, Xuefeng and Hanxian, cover a total area of 131,000 square meters and have a 4,000-acre high-quality southern yew planting base.
通過國家(jia)藥品GMP認證(zheng)
Obtained National Drug GMP Certification
首次通(tong)過國家高技術企業(ye)資格認證
First-time accreditation as a National High-Tech Enterprise
旗下(xia)南方(fang)制藥公(gong)司新三板上市(證券代碼(ma):831207)
South Pharmaceutical Company, a subsidiary, listed on the New Third Board (Securities Code: 831207)
通過美國FDA現場審計
Passed on-site audit by the U.S. Food and Drug Administration (FDA)
榮獲高(gao)新技術(shu)企業、國家林業重點龍(long)頭企業等稱號(hao)
Honored with titles such as High-Tech Enterprise and National Forestry Key Leading Enterprise
通過歐(ou)盟EDQM藥(yao)品質量認證
Passed the European Directorate for the Quality of Medicines & HealthCare (EDQM) certification for drug quality
榮獲(huo)國家專精特新“小巨人”企業稱號
2021: Awarded the title of "National Specialized and Innovative 'Small Giant' Enterprise"
與上海熙(xi)華藥業合作,投資「福建熙(xi)華醫藥產業園」
Cooperated with Shanghai Xihua Pharmaceutical Industry to invest in the 「Fujian Xihua Pharmaceutical Industrial Park」